Arvinas
This lab-focused, hands-on scientific role drives neuroscience discovery programs through biochemical, immunocytochemical, and histochemical pharmacology readouts, with a focus on primary cells and tissues of the CNS. The position requires expertise in high-content imaging, plate-based pharmacology, and target validation to support program decision-making and collaborate across multiple project teams. The role involves designing and implementing in vitro pharmacology assays, providing technical leadership in immuno-histochemical endpoints, and interfacing with the automated biology organization to transfer automation-ready assays.
Headquarters
New Haven, Connecticut, United States
Company Size
201-500 employees
Founded
2013
Arvinas is a biotechnology company pioneering targeted protein degradation therapeutics using its proprietary PROTAC (proteolysis-targeting chimera) platform, which designs small molecules that selectively induce degradation of disease-causing proteins rather than merely inhibiting them. The company develops therapies across oncology and neuroscience, and has achieved its first FDA-approved product, VEPPANU (vepdegestrant). Arvinas also partners with leading pharmaceutical companies and academic experts to broaden and accelerate its pipeline of protein degrader treatments.
Arvinas Stock Pre-Market (+4.7%): Broad Biotech Rally on Geopolitical De-escalation, Falling Oil
3 days ago
Arvinas Highlights Phase 1 Shift, 2026 Data Catalysts, and Vepdegestrant NDA at Barclays Conference
2 days ago
New CEO at local biotech firm is leading shift to early-stage drugs
2 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Arvinas.
Arvinas didn’t post a salary, so this is our estimate from similar listings.
Right around the average for this role
Arvinas (NASDAQ:ARVN) Shares Down 7.8% - What's Next?
1 day ago
In-vitro pharmacologist
Integrated Resources INC
Scientist I/II in In Vitro Pharmacology
Zealand Pharma
Scientist I/II in In Vitro Pharmacology
Zealand Pharma
Senior Scientist to Principal Scientist, in vitro Biology
Structure Therapeutics
Pharmacology Scientist
Pfizer
TEMP - Scientist, Lead Generation Biology
Neurocrine Biosciences